Key Highlights

  • Retension Pharma (NASDAQ:RTSN) priced an upsized IPO of 3.75 million shares at USD 12.00, raising USD 45 million, with trading expected from October 9, 2026 and closing on October 13; first-day trading is unverified.
  • Firmus, backed by Nvidia (NASDAQ:NVDA), scrapped what would have been Australia's second-largest IPO on October 9, citing market volatility, while partner Maas Group fell 22% on Thursday and 6.7% on Friday.
  • Jeff Bezos said a Blue Origin IPO could make sense after a USD 10 billion raise at about USD 140 billion, while SpaceX (NASDAQ:SPCX) closed at USD 160.57, down 4.19%, then rose 2.3% after hours.
  • Distribution Solutions (NASDAQ:DSGR) announced an upsized USD 800 million debt financing to support a take-private at USD 35 per share, though the amount comes from a single foreign summary, so it needs checking. Financing risk remains with yields high.

Retension Pharma (NASDAQ:RTSN): A Small Biotech Gets Done

Retension Pharma (NASDAQ:RTSN) priced an upsized IPO on October 8, 2026, selling 3.75 million shares at USD 12.00 for gross proceeds of USD 45 million, simple arithmetic that matches the pricing release. Trading is expected from October 9 and closing on October 13. Upsizing means the company sold more shares than first planned, which often reflects demand during bookbuilding, though it does not guarantee a first-day gain. Biotech IPOs fund clinical trials for companies with no product revenue, so the share price depends on trial results and the ability to raise more capital. Early investors may face a lock-up, often 180 days, which is a general term and not from the file. The deal shows that small healthcare listings can still price despite a weak tape, with the Nasdaq Composite down 1.25% on October 8. Retension Pharma (NASDAQ:RTSN) readers should check the opening print and read the prospectus. Investors should also note that the closing date of October 13 could shift and that an underwriter overallotment option may increase the final share count. Small deals are easier to place because they need fewer buyers, while large deals depend on broad institutional demand.

Nvidia (NASDAQ:NVDA): A Backer Watches an IPO Fail

Firmus, an AI data center developer backed by Nvidia (NASDAQ:NVDA), withdrew its Australian IPO on October 9, citing market volatility. The deal would have been the country's second-largest listing, and a factbox cited a valuation of about 30.6 billion in an unclear currency, so the number is flagged. Maas Group, a partner, fell 22% on October 8 and 6.7% on October 9, according to the file. IPO pricing depends on investor appetite, which falls when stocks drop and yields rise: the Nasdaq Composite lost 1.25% and the 10-year Treasury yield touched about 5.35% on October 8. Nvidia (NASDAQ:NVDA) closed at USD 230.48, down about 2.9%, as AI infrastructure names sold off. The withdrawal does not mean the business has failed, and Firmus may raise money privately instead. Nvidia's exposure to Firmus is not described in the file. Other AI infrastructure IPOs could be delayed if volatility persists, and Firmus may relist, raise private funds or change plans. Details about its backing, valuation currency and any new timetable should be checked directly in the company announcement. Australian IPO windows are small, so one cancellation can change how bankers view the pipeline for other AI infrastructure names there.

SpaceX (NASDAQ:SPCX): A Benchmark for Space IPOs

Jeff Bezos said in interview remarks that a Blue Origin IPO could make sense after a USD 10 billion raise at about a USD 140 billion valuation, which would sell about 7.1% of the company if the valuation is post-money, simple arithmetic. Blue Origin is private, so it has no ticker, and no filing or date was given. SpaceX (NASDAQ:SPCX) is the listed benchmark: it closed on October 8 at USD 160.57, down 4.19%, then rose 2.3% after hours to USD 164.30, a session that also included a spectrum deal that hit wireless carriers in extended trading. A second large space listing would give investors another choice and a valuation comparison, though the two firms differ in revenue, launch cadence and satellite businesses. Risks include a weaker IPO market, regulatory review and launch failures. SpaceX (NASDAQ:SPCX) remains volatile. Investors should watch for a confidential filing, a formal funding round, launch milestones and the performance of SpaceX shares. Private company valuations are not market prices, and comments in interviews are not commitments to list.

Distribution Solutions (NASDAQ:DSGR): Debt Behind a Take-Private

Distribution Solutions (NASDAQ:DSGR) disclosed on October 8 that it is raising an upsized USD 800 million of debt for a take-private at USD 35 per share, in a Rule 135c announcement, which permits a limited notice of an unregistered notes offering. Upsized means the amount was increased from an earlier plan, which usually indicates lender demand, though the original size is not given. In a leveraged buyout, notes sold to institutional investors can replace bridge loans arranged at signing, and the cash price of USD 35 per share is what public holders would receive if the deal closes. The file gives no coupon, maturity, premium or buyer, and the amount comes from a single foreign summary, so the release or an 8-K should be read. With the 10-year Treasury yield near 5.35%, financing costs are high. Distribution Solutions (NASDAQ:DSGR) holders should watch the vote and closing. The Federal Reserve meets October 27 and 28, 2026. Investors should also watch the pricing of the notes, the proxy statement and any regulatory steps that could delay completion or force a change in financing terms.

Where Things Stand

Capital markets were open but selective. Retension Pharma (NASDAQ:RTSN) got its small deal done. Firmus, backed by Nvidia (NASDAQ:NVDA), pulled a large listing. Bezos floated a Blue Origin IPO, which makes SpaceX (NASDAQ:SPCX) the benchmark to watch. Distribution Solutions (NASDAQ:DSGR) showed that debt markets still fund buyouts. The evidence suggests that small, well-priced deals can proceed while large, valuation-sensitive ones wait. The common thread is price sensitivity: buyers still act when terms are right, and the Federal Reserve meeting on October 27 and 28, 2026 may shape the next round of decisions. Readers should treat each item as a snapshot, since prices, filings and timetables can all change quickly.